Drug profile · INN
anagrelide
ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN)
anagrelide (ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN)) is a phosphodiesterase 3 inhibitor. Associated with Takeda.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX35
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — anagrelide
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
anagrelide (ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN)) is a phosphodiesterase 3 inhibitor. Associated with Takeda.
Key facts
INN anagrelide
Brand ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN)
Mechanism Phosphodiesterase 3 inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX35
Originator Takeda
Mechanism of action
Phosphodiesterase 3 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is anagrelide?
anagrelide (ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN)) is a phosphodiesterase 3 inhibitor. Associated with Takeda.
What is the brand name for anagrelide?
ANAGRELIDE VIATRIS (PREVIOUSLY ANAGRELIDE MYLAN) is a marketed brand name for anagrelide. Check FDA Drugs@FDA for the current US label holder and prescribing information.